We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Niox Group Plc | NIOX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 2.00 | 3.28% | 63.00 | 16:35:28 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 61.00 | 60.80 | 62.00 | 63.00 | 61.00 |
| Industry Sector |
|---|
| BEVERAGES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 26/03/2024 | Final | GBP | 0.01 | 23/05/2024 | 24/05/2024 | 24/06/2024 |
| 07/06/2023 | Special | GBP | 0.025 | 17/08/2023 | 18/08/2023 | 15/09/2023 |
| Top Posts |
|---|
Posted at 16/1/2025 17:05 by eezymunny Never researched this one until today. Looks a nice little company but there seems to be plenty of competition. Anything special about the NIOX kit that all the others can't do? Gross margin most recently 72%. Is that defendable?Just Google "feno testing equipment" to see some competitors. |
Posted at 06/1/2025 23:24 by earwacks I thought so too. Not sure why Griffith has been so persistently selling down. Presumably has better opportunities. I know he has been building a stake in Dlar this year. I switched to Renx, Vrci and topped up in Cog, all up over 30 percent over Christmas period. I think Niox is ok but the vaccination and Griffiths sell off spooked me a bit, but mostly I see better opportunities in Renx particularly and had no spare cash. Niox should be ok with the updated FeNox and home kit development, but they are just paying back the cash they make to shareholders for the two years with no real goal for development in any other area. Could get bought out, but quite a risk as all their eggs in one basket. Unlikely there will be a total cure for asthma for a while ye, so the dividends should flow, but not sure how strong growth will be. How much of the market will the home kit test be and will it impact on the the surgery test? I don’t know really. Has far to big a holding and decided I needed to get much more diversified from five holdings 60 percent of which was in Niox. Obviously still plenty of demand for their shares as had no problem selling.gl |
Posted at 02/12/2024 19:09 by edwardt Surely that is not good for niox! |
Posted at 23/10/2024 10:45 by earwacks Clearly there has been some selling yesterday but quite a few buying back in presumably re-investing winnings. I fully intend to do the same. Just a question of timing. We won’t get another TU update till late January. A lot depends on what mr Griffiths and co do. I think there will be plenty of appetite even if they do offload a few more. Singer have reinstated their buy recommendation even though not increasing revenue upgrade but they have increased the EBITDA ad raised share price target siting further payouts as they accumulate cash again. 5 brokers have targets in a range of 69-91p. The good thing is some kind of dividend or payout is pretty certain plus we don’t yet know how the new upgraded version will sell. They are going to push sales and hoping to grow substantially in the USA. Then there will hopefully be further updates on home test developments. I’m not entirely convinced by Mills suggesting most of the money has been made here. It has more than doubled from its low, but I can see a buyout price in excess of £1.00 per share, although unfortunately probably not Astra (they could buy this with a days revenue possibly). Wallet investor have a 5 year target of £2.67!Maybe many stocks can outstrip that. In the meantime it is definitely a core holding and nice little earner with a 5 percent annual return. GL |
Posted at 22/10/2024 18:17 by wjccghcc You've effectively sold some of your shares to the company at 80p so I'd have thought it's a capital gain. If it were a special dividend, then it would be income. |
Posted at 22/10/2024 16:08 by ricatcoatham I have received the money from the tender offer today. Does any poster know how it should be classed for tax purpose ie dividend or capital gain. |
Posted at 21/7/2024 18:37 by badday Gets a mention on the Paul Scott podcast ( always worth a listen)Interesting that he says Christopher Mills due to do Paul Hills (Vox Markets) interview next week. Christopher Mills was thinking it was fully valued for now, but growing into that value. Might have something to say Anyway Paul Scott comments below: “Another interesting company that I've gone green on, which might surprise you, because it's not my usual sort of value share, is a thing called NIOX, N-I-O-X. That put a trading update out. I had another refresh of the figures. It's quite pricey, but it does something to do with asthma products. And look at the shareholder list on that. You've got Harwood, you've got AstraZeneca, and you've got somebody else who owned about a third of the shares, who were all big name major investors. So the way I look at it is, they've done the due diligence for us, haven't they? And they obviously think it's good, although... Oh, that was it, Rathbones had bought some shares from the other two big shareholders. Richard Griffith, I think, was the other one who's got a big position there. He doesn't get everything right, nobody does, but he's certainly a smart cookie. Anyway, so Niox, I think, is worth you having a look at.” From Small Caps Podcast with Paul Scott: Episode 29 (20 July 2024) - UK Small/Mid Caps with Paul Scott, 20 Jul 2024 This material may be protected by copyright. |
Posted at 02/5/2024 07:37 by earwacks Have been delving further back into Circassia history. This is looking one of the more bizar Aim stories and there have been many. Apparently cir floated at £3.60 back in the day. Something to do with cat allergies! Thats me. My partner has two. Nightmare, but we also have a dog to defend me. Anyway obviously cir was a complete crackpot company under old management and got badly tangled up with Astra. Guess who came out on top? However Ian Johnson, like Chris Mills I clocked when he took Bioquel on a very successful journey about the same time as Cir were in their early days. Quite how Johnson came to Cir to take the reigns I’m not sure, but he certainly worked his magic on it. Just watched an old video of Andy Brough (schroders)talking about how he always gets interested when he hears Chris Mills is involved on the board of a biotech. I remember Mills saying all the serious money had been made on Niox when it was 50p, and it couldnt make 60p under its own steam, inferring a buyout I guess. It went on up to 75p under its own steam with a little help from a special dividend payout. Subsequently it fell back a bit. People keep saying its expensive, but I feel that is only when looking at current valuations. I remember valuations in companies being a lot higher than this pre Covid. Recently Niox have offered employees a 3 year savings plan for shares at 51p which I find curious. In light of recent developments with COPD, the upgrading of a new FeNo diagnostic instrument (the old one having a 5 year max shelf life limit) and the development of a home diagnostic kit, I find myself thinking these shares are bloody cheap still. Incidentally Mills is on the board of EKF (I have a smaller portion) and has made two £100,000 this year, one very recently when they announced results which as expected were not great. But they make enzymes! Or are trying to. He also has connections with Vrci and Renx, (kidney diagnostics) both of which have come off the boil a bit. Tempted for a small position, but they would definitely stretch my risk appetite. And why not just stick with what you know, Niox! |
Posted at 30/4/2024 07:58 by earwacks Edward. Sounds fantastic. If successful that doubly underestimates the potential for Niox. Even Chris Mills seems to have not understood Niox. I think it was last year he commented Niox couldn’t reach 60p under its own steam! It smashed through that in a couple of months. He has been very bullish and it was him that flagged up the humongous tax credit. Personally I thought a target by one broker of £1.20 under its own steam was not pie in the sky considering 95 percent of their market is up for grabs. Requires replacing every 5 years depending on usage. Mills did point out this is a razor blade stock. Sounds like they have also reinvented another Gillette. dividend declared for next months and possibly another special on the cards. Have to admit this is now about a third of my portfolio and am not interested in top slicing. I have a few duffers in my portfolio but would rather kick them out frankly. My best pick since Arm holdings. Gl |
Posted at 27/4/2024 14:19 by earwacks Astra dissolved their partnership with Circassia over Tudorza and Duklar inhaler for COPD.Astra retained commercial rights in consideration of 150 million dollar debt and retained 18 percent of Circassia, now Niox. Astra have since offloaded this product. Not sure how successful it has been. Probably nothing like the FeNo tester. What Niox have is the development of the best Asthma diagnostic device and 600 million tax credit for the Circassia debacle. Meaning they will never pay tax on their very cash generative device. The tax credit is also transferable which makes it an added asset to their £270 million market cap. The directors are probably nearing retirement. They have built a highly profitable business from the wreckage of Circassia, making it a market leader in its field, but still only tapping 5 percent of possible world market. Added to that they are developing a domestic kit, which if successful will probably appeal to a us pharma giant, not necessarily just Astra, who as you say may not be interested as it is Gsk that have recently purchased a company that have developed an asthma drug. Potential for Niox is pretty big and are at an interesting stage where they might need some serious gearing up to reach potential global markets, whilst having converted themselves into a growing cash machine. Although expensive on last years results I don’t think forecasters have quite got their head around the potential of Niox yet |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
